High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan

Cancer Letters

Volumn 207, Issue 1, 2004, Pages 59-67

  Chen, Fang Ming ^a   Hou, Ming Feng ^a   Wang, Jaw Yuan ^a   Chen, Tsung Chi ^a   Chen, David C P ^b   Huang, Sung Yu ^b   Chung, Yi Shu ^b   Lin, Shiu Ru ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b 10130 Sorrento Valley Road   (United States)

Author keywords

Breast cancer; HER2; P53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EVALUATION; EXON; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; TAIWAN;

BREAST NEOPLASMS; CODON; DNA MUTATIONAL ANALYSIS; EXONS; GENES, P53; HUMANS; MUTATION; MUTATION, MISSENSE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, ERBB-2; SEQUENCE ANALYSIS, DNA; TAIWAN; TREATMENT OUTCOME;

EID: 1842473022     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.12.005     Document Type: Article

References (45)

1. Higginson J., Muir C.S., Munoz N. Human cancer: epidemiology and environmental causes. In: Anonymous. Cambridge Monographs on Cancer Research. 1992;Cambridge University Press, Cambridge. pp. 377-387.
2. Health Statistics, Department of Health, Taiwan, 2000.
3. Yang P.S., Yang T.L., Liu C.L., Wu C.W., Shen C.Y. A case-control study of breast cancer in Taiwan - a low incidence area. Br. J. Cancer. 75:1997;752-756.
4. Lacey J.V. Jr., Devesa S.S., Brinton L.A. Recent trends in breast cancer incidence and mortality. Environ. Mol. Mutagen. 39:2002;82-88.
5. Epidemiology of the principal cancers, Department of Health, Taiwan, 1999.
6. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
7. Soussi T., Dehouche K., Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat. 15:2000;105-113.
8. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
9. Bates S., Phillips A.C., Clark P.A. p14(ARF) links the tumor suppressors RB and p53. Nature. 395:1998;124-125.
10. Graeber T.G., Osmanian C., Jacks T. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 379:1996;88-91.
11. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 8:1997;323-331.
12. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B., Stark G.R. The p53 network. J. Biol. Chem. 273:1998;1-4.
13. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M.S., Hovig E., et al. Database of p53 gene somatic mutations in human tumors cell lines: updated compilation and future prospects. Nucleic Acids Res. 25:1997;151-157.
14. Iwaya K., Tsuda H., Hiraide H., Tamaki K., Tamakuma S., Fukutomi T., et al. Nuclear p53 inimunoreaction associated with poor prognosis of breast cancer. Jpn. J. Cancer Res. 82:1991;835-840.
15. Andersen T.I., Holm R., Nesland J.M., Heimdal K.R., Ottestad L., Børresen A.L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer. 68:1993;540-549.
16. Kovach J.S., Hartmann A., Blaszyk H., Cunningham J., Schaid D., Sommer S.S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl Acad. Sci. USA. 93:1996;1093-1096.
17. Bergh J., Norberg T., Sjögren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1:1995;1029-1034.
18. Aas T., Børresen A.L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J.E., et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2:1996;811-814.
19. Bertheau P., Plassa F., Espie M., Turpin E., de Roquancourt A., Marty M., et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet. 2002;852-854.
20. Geisler S., Lonning P.E., Aas T., Johnsen H., Fluge O., Haugen D., et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2001;2505-2512.
21. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 1991;49-53.
22. Hartmann A. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet. 1997;27-33.
23. Tsai K.B., Hou M.F., Lin H.J., Chai C.Y., Liu C.S., Huang T.J. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer. Kaohsiung J. Med. Sci. 2001;64-76.
24. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning. A Laboratory Manual. 2nd ed. 1989;Cold Spring Harbor Laboratory, New York.
25. Wang J.Y., Lin S.R., Hsieh J.S., Hsu C.H., Huang Y.S., Huang T.J. Mutations of p53 gene in gastric carcinoma in Taiwan. Anticancer Res. 2001;513-520.
26. Olivier M., Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin. Cancer Biol. 2001;353-360.
27. Lou M.A., Tseng S.L., Chang S.F., Yue C.T., Chang B.L., Chou C.H., et al. Novel patterns of p53 abnormality in breast cancer from Taiwan: experience from a low-incidence area. Br. J. Cancer. 1997;746-751.
28. Gong Z.Y., Wong K.W., Li Y., Mao Y.R., Lung M.L. p53 inactivating mutations in Chinese breast carcinomas. Oncol. Rep. 2000;381-385.
29. Sasa M., Kondo K., Komaki K., Uyama T., Morimoto T., Monden Y. Frequency of spontaneous p53 mutations (CpG site) in breast cancer in Japan. Breast Cancer Res. Treat. 1993;247-252.
30. Blaszyk H., Hartmann A., Tamura Y., Saitoh S., Cunningham J.M., McGovern R.M., et al. Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations. Oncogene. 13:1996;2159-2166.
31. Kang J.H., Kim S.J., Noh D.Y., Choe K.J., Lee E.S., Kang H.S. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. J. Mol. Med. 2001;648-655.
32. Tsuda H., Iwaya K., Fukutomi T., Hirohashi S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn. J. Cancer Res. 1993;394-401.
33. Hartmann A., Blaszyk H., Saitoh S., Tsushima K., Tamura Y., Cunningham J.M., et al. High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br. J. Cancer. 1996;896-901.
34. Done S.J., Eskandarian S., Bull S., Redston M., Andrulis I.L. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J. Natl Cancer Inst. 93:2001;700-704.
35. Soong R., Iacopetta B.J., Harvey J.M., Sterrett G.F., Dawkins H.J., Hahnel R., Robbins P.D. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int. J. Cancer. 74:1997;642-647.
36. Iacopetta B., Grieu F., Powell B., Soong R., McCaul K., Seshadri R. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin. Cancer Res. 4:1998;1597-1602.
37. Norberg T., Klaar S., Karf G., Nordgren H., Holmberg L., Bergh J. Increased p53 mutation frequency during tumor progression - results from a breast cancer cohort. Cancer Res. 61:2001;8317-8321.
38. Blaszyk H., Hartmann A., Cunningham J.M., Schaid D., Wold L.E., Kovach J.S., Sommer S.S. A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int. J. Cancer. 89:2000;32-38.
39. Pharoah P.D., Day N.E., Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br. J. Cancer. 80:1999;1968-1973.
40. Collins D.W., Jukes T.H. Rates of transition and transversion in coding sequences since the human-rodent divergence. Genomics. 20:1994;386-396.
41. D.N. Cooper, M. Krawczak, S.E. Antonorakis, The nature and mechanisms of human gene mutation, In: C. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (eds.) Metabolic and Molecular Bases of Inherited Disease, 7th ed., McGraw-Hill, New York, (1995) 259-291.
42. Toyooka S., Tsuda T., Gazdar A.F. The TP53 gene, tobacco exposure, and lung cancer. Hum. Mutat. 21:2003;229-239.
43. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:1991;427-428.
44. Dogliotti E., Hainaut P., Hernandez T., D'Errico M., DeMarini D.M. Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes. Recent Results Cancer Res. 154:1998;97-124.
45. Olivier M., Eeles R., Holistein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum. Mutat. 19:2002;607-714.